Related Experiment Videos
NR2B selective NMDA receptor antagonists.
Sham S Nikam1, Leonard T Meltzer
1Department of Chemistry, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. sham.nikam@pfizer.com
Current Pharmaceutical Design
|April 12, 2002
Summary
NR2B antagonists show promise for treating neurological conditions like Parkinson's disease and pain. Recent advances in chemical leads offer new therapeutic potential.
Area of Science:
- Neuroscience
- Pharmacology
- Medicinal Chemistry
Background:
- NR2B antagonists are a class of excitatory amino acid receptor antagonists.
- They have demonstrated efficacy in preclinical models for neuroprotection, pain relief, and Parkinson's disease.
- Benzylpiperidine and phenylpiperidine scaffolds, based on Ifenprodil and Eliprodil, have historically guided research.
Purpose of the Study:
- To review the development and therapeutic potential of NR2B antagonists.
- To highlight recent advancements in chemical leads and novel structural templates.
- To discuss the ongoing efforts in developing NR2B antagonists as therapeutic agents.
Main Methods:
- Review of scientific literature and patent filings.
- Analysis of structure-activity relationships (SAR) of NR2B antagonists.
- Identification and discussion of key chemical leads and their developers.
Main Results:
- Several NR2B antagonist chemical leads, including CP-101,606, Ro25,6981, and PD0196860, have been identified.
- New biaryl-based NR2B antagonists have been reported by Merck and Roche.
- Significant research interest from both industrial and academic groups is evident.
Conclusions:
- NR2B antagonists hold significant therapeutic promise for various pathophysiological indications.
- Recent chemical advancements suggest a positive outlook for the clinical success of these agents.
- Continued research is crucial for translating these findings into effective treatments.